SCHEMBL23488209

SCHEMBL23488209

COc1cc(OCc2cccc(NC(=O)CCCCCCC(=O)O)c2)c(Cl)cc1C(=O)O[C@H]1[C@@H](OC)O[C@H](CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.39
LGALS3 P17931 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
LGALS9 O00182 1/20 0.39
LGALS1 P09382 1/20 0.39
LGALS7; LGALS7B P47929 1/20 0.39
LGALS8 O00214 2/20 0.37
HPGD P15428 1/20 0.35
ERBB2 P04626 1/20 0.35
LGALS4 P56470 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488206 0.98 LGALS3 (0.39) EGFRLGALS3HDAC3HDAC4HDAC1
SCHEMBL23488235 0.96 LGALS3 (0.40) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488768 0.92 HDAC8 (0.38) EGFRLGALS3HDAC3HDAC4HDAC1
SCHEMBL23488585 0.90 LGALS3 (0.40) LGALS3HDAC3HDAC1HDAC2HDAC10
SCHEMBL23488340 0.90 EGFR (0.37) EGFRLGALS3HDAC3HDAC4HDAC1
SCHEMBL23488226 0.89 LGALS3 (0.38) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488338 0.89 LGALS3 (0.38) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488343 0.88 LGALS3 (0.41) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488174 0.88 LGALS3 (0.40) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488578 0.87 LGALS3 (0.41) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 EGFR 1469/4885LGALS3 156/4885HDAC3 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.